bioMérieux (BIM) Q1 2025 TU earnings summary

Executive summary

• Q1 2025 sales reached €1.1 billion, representing 13% organic growth year-over-year, with strong performance in respiratory panels and industrial applications.

• BIOFIRE Respiratory Panel sales surged 21% organically, driven by a historic flu season, especially in North America and EMEA.

• SPOTFIRE installations hit a record, with over 1,400 instruments installed in Q1, reflecting robust U.S. and Japanese demand, aided by government subsidies in Japan.

• Achieved fifth consecutive quarter of double-digit organic growth, supported by the GO•28 strategic plan and all four growth drivers up 11.8%.

• 2025 guidance reaffirmed for at least 7% sales and 10% CEBIT growth at constant scope and exchange rates.

Financial highlights

• Q1 2025 consolidated sales reached €1,098 million, up 13.7% as reported and 13% organically year-over-year.

• Positive currency effect of €11 million in Q1, mainly due to a strong U.S. dollar in early 2025.

• SPOTFIRE sales reached €54 million, up over 160% organically.

• Clinical Applications (85% of sales) grew 13% to €938 million; Molecular Biology up 25%, BIOFIRE up 18%.

• Industrial Applications (15% of sales) grew 9%, led by Pharma Quality Control reagents.

Outlook and guidance

• 2025 guidance reaffirmed: at least 7% sales growth and at least 10% CEBIT growth at constant exchange rates.

• Currency effect now expected to negatively impact 2025 CEBIT by €35m to €40m.

• SPOTFIRE sales target for 2025 remains €190 million, aiming to double 2024 sales.